Drotrecogin Alfa (Activated) May Attenuate Severe Sepsis-Associated Encephalopathy in Clinical Septic Shock

Critical Care - United Kingdom
doi 10.1186/cc8947
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Introduction: Severe Sepsis and Drotrecogin Alfa (Activated)

Critical Care
Critical CareIntensive Care Medicine
2007English

Drotrecogin Alfa Activated as a Treatment for Severe Sepsis in Pediatric Cancer

Bone Marrow Transplantation
TransplantationHematology
2006English

Drotrecogin Alfa (Activated)

European Journal of Anaesthesiology
AnesthesiologyPain Medicine
2008English

Sepsis Bundle Adherence Is Associated With Improved Survival in Severe Sepsis or Septic Shock

Western Journal of Emergency Medicine
MedicineEmergency Medicine
1996English

Sepsis, Severe Sepsis and Septic Shock in Adults and Anaesthesia

Southern African Journal of Anaesthesia and Analgesia
AnesthesiologyPain Medicine
2002English

The Safety Profile of Drotrecogin Alfa (Activated)

Critical Care
Critical CareIntensive Care Medicine
2007English

Sepsis, Severe Sepsis and Septic Shock: Changes in Incidence, Pathogens and Outcomes

Expert Review of Anti-Infective Therapy
VirologyInfectious DiseasesMicrobiology
2012English

Drotrecogin Alfa in Patients With Severe Sepsis: Experience From a Tertiary Care Center in North India

Critical Care
Critical CareIntensive Care Medicine
2007English

Diagnosis of Adrenal Insufficiency in Severe Sepsis and Septic Shock

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy